tailieunhanh - báo cáo khoa học: "A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from China"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài:A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from China | Journal of Hematology Oncology BioMed Central Open Access Short report A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia a single center experience from China Jianmin Wang t Shuqing Luf Jianmin Yang Xianmin Song Li Chen Chongmei Huang Jun Hou and Weiping Zhang Address Department of Hematology Changhai Hospital Second Military Medical University Shanghai PR China Email Jianmin Wang - jmwang@ Shuqing Lu - lsq7219@ Jianmin Yang - yang3401@ Xianmin Song - shongxm@ Li Chen - yuhe0628@ Chongmei Huang - huangchongmei@ Jun Hou - houjun@ Weiping Zhang - zhangwp@ Corresponding author fEqual contributors Published 30 July 2009 Received 1 June 2009 Journal of Hematology Oncology 2009 2 32 doi 1756-8722-2-32 Accepted 30 July 2009 This article is available from http content 2 1 32 2009 Wang et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background and purpose The response to remission induction in elderly patients with acute myeloid leukemia AML remains poor. The purpose of this paper is to evaluate the efficacy and toxicity of a plant alkaloid homoharringtonine in combination with cytarabine as an induction therapy for AML in elderly patients 60 years . Results Twenty-three patients were treated with the HA regimen consisting of homoharringtonine 2 mg m2 day for 7 days and cytarabine Ara-C 100 mg m2 day for 7 days . The overall response rate was with complete remission CR rate of and partial remission of . There was no early death in this cohort of patients. The estimated median overall survival OS time of all patients was months. The .